Abstract: The present invention relates to polydixylitol polymer based gene transporter (PdXYP) and a preparation method thereof. Further, the present invention relates to a nucleic acid delivery complex where the nucleic acids for treatment are conjugated to the gene transporter and a pharmaceutical composition for gene therapy including the complex as an active ingredient. In addition, the present invention relates to the gene transporter, gene delivery complex, and gene therapy using the gene transporter and gene delivery complex. It was confirmed that the PdXYP of the present invention has a considerably higher nucleic acid delivery rate than existing gene transporters, has almost no cytotoxicity in the conjugate when conjugated with DNA, also has very high in vivo transfection efficiency, and above all, especially has considerably high transfection efficiency for brain tissues, which has involved difficulty in gene therapy due to the blood brain barrier for a while.

Abstract: The present disclosure relates to a thiolated hydroxypropyl methylcellulose phthalate (T-HPMCP) drug delivery vehicle which is pH responsive and is loaded with either a protein drug or an antigen, to T-HPMCP microparticles, and to a production method for an ileum-specific, pH responsive, T-HPMCP drug delivery vehicle, the method including a step of loading a protein drug or an antigen onto the T-HPMCP microparticles. The T-HPMCP microparticles of the present disclosure are soluble in chlorinated methane because of the introduction of the thiol group, while a T-HPMCP drug delivery vehicle produced from the particles can efficiently effect in vivo delivery of the protein drug or antigen which is loaded thereon, since said vehicle is pH responsive such that the in vivo residence time is extended and the vehicle can act specifically on the ileum.

Abstract: The present invention relates to polydixylitol polymer based gene transporter (PdXYP) and a preparation method thereof. Further, the present invention relates to a nucleic acid delivery complex where the nucleic acids for treatment are conjugated to the gene transporter and a pharmaceutical composition for gene therapy including the complex as an active ingredient. In addition, the present invention relates to the gene transporter, gene delivery complex, and gene therapy using the gene transporter and gene delivery complex. It was confirmed that the PdXYP of the present invention has a considerably higher nucleic acid delivery rate than existing gene transporters, has almost no cytotoxicity in the conjugate when conjugated with DNA, also has very high in vivo transfection efficiency, and above all, especially has considerably high transfection efficiency for brain tissues, which has involved difficulty in gene therapy due to the blood brain barrier for a while.

Abstract: The present invention relates to a biodegradable polysorbitol-based osmotically active transporter (PSOAT) and gene therapy using the same as a gene carrier. The biodegradable polysorbitol-based osmotically active transporter (PSOAT) of the present invention includes a sorbitol skeleton, which imparts an osmotic pressure to the cell membrane to improve membrane permeability, thereby exhibiting remarkably improved transfection efficiency. Further, the polysorbitol-based osmotically active transporter of the present invention exhibits high DNA binding ability, effectively protects DNA from nuclease, exhibits physicochemical properties suitable for use as a gene carrier, and has very low cytotoxicity in vitro and in vivo, thereby capable of being used as a gene carrier for gene therapy.

Abstract: The present invention relates to a magnetic resonance imaging (MRI) contrast agent coated with carboxylated mannan, particularly a carboxylated mannan coated superparamagnetic MRI contrast agent specifically targeting antigen presenting cells and having excellent in vivo stability, and a method for producing the same. The MRI contrast agent coated with carboxylated mannan of the present invention can provide excellent in vivo stability and biocompatibility owing to its high surface negative charge, and can be introduced specifically into antigen presenting cells owing to mannose of mannan, so as to visualize the antigen presenting cells and the tissue containing the antigen presenting cells in MRI.

Abstract: The present invention relates to a biodegradable polysorbitol-based osmotically active transporter (PSOAT) and gene therapy using the same as a gene carrier. The biodegradable polysorbitol-based osmotically active transporter (PSOAT) of the present invention includes a sorbitol skeleton, which imparts an osmotic pressure to the cell membrane to improve membrane permeability, thereby exhibiting remarkably improved transfection efficiency. Further, the polysorbitol-based osmotically active transporter of the present invention exhibits high DNA binding ability, effectively protects DNA from nuclease, exhibits physicochemical properties suitable for use as a gene carrier, and has very low cytotoxicity in vitro and in vivo, thereby capable of being used as a gene carrier for gene therapy.

Abstract: The present invention relates to a magnetic resonance imaging (MRI) contrast agent coated with carboxylated mannan, particularly a carboxylated mannan coated superparamagnetic MRI contrast agent specifically targeting antigen presenting cells and having excellent in vivo stability, and a method for producing the same. The MRI contrast agent coated with carboxylated mannan of the present invention can provide excellent in vivo stability and biocompatibility owing to its high surface negative charge, and can be introduced specifically into antigen presenting cells owing to mannose of mannan, so as to visualize the antigen presenting cells and the tissue containing the antigen presenting cells in MRI.

Abstract: Disclosed herein is a biopolymer/gene complex for the aerosol delivery of a gene. The biopolymer/gene complex comprises a polyethyleneimine (PEI) having a substitution of glucose for at least a portion of the primary amino groups of the polyethyleneimine, and the content of the polyethyleneimine is 2-4 times the content of the gene. Also, disclosed is a lung cancer therapeutic agent comprising a biopolymer/gene complex including a polyethyleneimine (PEI) having a substitution of glucose for 30-40 mol % of the primary amino groups of the polyethyleneimine, and a gene encoding PTEN, in which the content of the polyethyleneimine is 2-4 times the content of the gene.

Abstract: Disclosed herein is a gene therapeutic agent and pharmaceutical composition for the prevention and treatment of lung cancer. For aerosol delivery, chemically synthesized polyester amine is used as a carrier in the gene therapeutic agent. The polyester amine/Akt1 siRNA complex is found to be effectively delivered to the lungs of K-ras null mice through a nose-only inhalation system and to significantly suppress lung cancer progression as denoted by gene delivery efficiency and inhibition of Akt-related signals and cell cycle. Thus, the aerosol delivery of polyester amine-mediated Akt1 siRNA is provided as an effective model for noninvasive gene therapy.